Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROOF 302
2019-003248-63Phase 3Terminated
- Sponsor
- QED Therapeutics
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Infigratinib with Placebo (2 arms). Primary endpoint: Centrally reviewed disease-free survival. Started Jan 2020; status: terminated.
02
Drugs
infigratinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2019-003248-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003248-63.